Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of Elacestrant.

The National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether new medicines should be routinely funded by the NHS based on an assessment of their costs and benefits. The NHS is legally required to fund medicines recommended by the NICE, and cancer medicines are eligible for funding from the Cancer Drugs Fund from the point of positive NICE draft guidance.

The NICE recommended elacestrant as an option for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment in final draft guidance on 19 December 2024, and it is now funded for eligible patients in England through the Cancer Drugs Fund. Final guidance is due to publish on 5 February 2025.